Agents in late-stage development for the treatment of osteoporosis and related bone disease.
Coherus Announces Lowest Price for Humira Biosimilar, Partners with Mark Cuban Cost PlusJune 2nd 2023
Coherus will launch Yusimry in July with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors); “the lowest price announced to date of any adalimumab offering in the United States,” the company said.
FDA Accepts BLA for Lifileucel for Difficult-to-Treat MelanomaMay 31st 2023
Lifileucel is a polyclonal tumor infiltrating lymphocyte (TIL) therapy designed for patients with advanced melanoma who have experienced progression after previous treatment with anti-PD-1/L1 therapy and targeted therapy.
New Heart Failure Med Will be Priced 'Competitively'May 30th 2023
Inpefa (sotagliflozin) is in the SGLT inhibitor class recommended as first-line treatment for heart failure by the American Heart Association and other groups. Jardiance (empaglifozin), a competitor in that class, has a list price of $570.48 for a month's supply.
2 Clarke Drive
Cranbury, NJ 08512